Navigation Links
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
Date:3/27/2008

FDA Approves Label Revisions Recommending New Weight-Based Dosing Regimen

KENILWORTH, N.J., March 27 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP) today reported that the U.S. Food and Drug Administration (FDA) has approved label revisions for PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for chronic hepatitis C, recommending weight-based dosing of REBETOL (800-1400 mg daily) based on patient body weight. The revised label also recommends a shorter, 24-week course of the combination therapy for patients with chronic hepatitis C virus (HCV) genotype 2 or 3.

The revisions represent the first FDA approval of a 1400 mg ribavirin dose and the widest ribavirin dosing range approved for use in combination with peginterferon for treating chronic hepatitis C in patients with compensated liver disease.

The label changes are based on the results of the WIN-R trial,(1) the largest U.S. hepatitis C study, conducted in more than 4,900 patients. The study showed that PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient body weight) resulted in a significantly higher sustained virologic response (SVR)(2) compared to PEGINTRON in combination with a flat 800 mg daily dose of REBETOL, the previously labeled dose. Importantly, the study reported low relapse rates consistent with other PEGINTRON studies.(3,4)

"PEGINTRON and weight-based ribavirin was significantly more effective than flat-dosed ribavirin, especially in genotype 1 patients, and provided consistent efficacy across all weight groups," said WIN-R principal investigator Ira M. Jacobson, M.D., Vincent Astor Professor of Clinical Medicine at Weill Medical College of Cornell University and chie
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
4. Obesity-Related Hormone is Higher in Children with Down Syndrome
5. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
6. BSGI Posts Higher Sensitivity than Mammography or MRI for the Detection of Ductal Carcinoma In Situ
7. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
8. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
9. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
10. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
11. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... 2011  Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE ) ... develops new uses for previously approved drugs and new ... publications about the Company by anonymous short sellers. The ... stock is a result of factually inaccurate and materially ...
... Thoratec Corporation (Nasdaq: THOR ), a ... save, support and restore failing hearts, today announced the ... directors.  "Bill brings tremendous skill, leadership, and ... to add him to our board of directors," said ...
Cached Medicine Technology:Ampio Responds to Recent Publications by Anonymous Short Sellers 2Thoratec Announces Appointment of William A. Hawkins to Board of Directors 2Thoratec Announces Appointment of William A. Hawkins to Board of Directors 3
(Date:7/9/2014)... and poor printing on prescription labels handed out ... to errors in taking medication, according to new ... (Canadian National Institute for the Blind)., The study, ... , found that labels on prescription medications dispensed ... guidelines for legibility. , By simply following recommended ...
(Date:7/9/2014)... published in the scientific journal Nature Neuroscience ... at Universit Laval, reveals that it is possible to ... rekindling pain so that it can subsequently be erased. ... chronic pain. , The researchers from the Faculty of ... mentale de Qubec (IUSMQ) were inspired by previous work ...
(Date:7/8/2014)... cardiovascular health as other healthy mature individuals, according to ... of Transplantation . The findings may provide some reassurance ... caring for them. , Over the past two decades, ... older has become more common. Given the links between ... of a kidney could make older donors vulnerable to ...
(Date:7/8/2014)... clinicians from Plymouth, UK, and Sydney, Australia, have today ... launched ACEmobile - a free-to-use app to support the ... the first of its kind; an iPad-based tool that ... through the whole process, meaning more members of the ... of assessment. Designed by clinicians for clinicians, ACEmobile also ...
(Date:7/8/2014)... discovered a biomarker that could give expecting mothers and ... predict that a pregnant woman may develop preeclampsia, at ... , Preeclampsia is a cardiovascular disorder generally occurring late ... creating immediate and potentially lifelong risks to both mother ... in the urine, and is typically diagnosed in the ...
Breaking Medicine News(10 mins):Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Discovery of a new means to erase pain 2Health News:Study finds kidney donation safe for healthy older adults 2Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3
... food energy, not just carbohydrates, appear to enhance memory ... in the American Journal of Clinical Nutrition.//”The positive effects ... but this is the first study to show that ... lead author Randall Kaplan. ,Until now, it was ...
... have derived a new gel to reduce the hair ... distressing side effects of the treatment of cancer. The ... which contains a drug known as GW8510, helped to ... ,Lead researcher Stephen Davis said the gel completely prevented ...
... her pregnancy, the special form of the disease, called gestational ... can develop high blood pressure or preeclampsia.// Their newborns are ... blood sugar under control, some women need to take a ... Now that task may get easier. ,Researchers in ...
... hormone replacement therapy appear to restore their cognitive function ... replacement therapy (HRT) can protect against dementia// is conflicting ... to demonstrate benefit.A new report, from researchers, is ... over 1,000 women from different countries for a few ...
... company has launched a revolutionary drug, Bonmax (raloxifene hydrochloride) ... is used in the prevention and treatment of postmenopausal ... which not only safe but can also be used ... due to the deficiency of the oestrogen hormone during ...
... benefit from investing in gymnasium membership and a exercise personal ... Cleavland University // it is better to exercise at home ... machines are often advertised in a misleading way. For instance, ... body, and you may need to learn certain skills - ...
Cached Medicine News:
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Short 19 mm. Overall length: 3.9 inches....
One end with needle point and other end with medium taper. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
The interface spatula can be used when irregular interface adherence occurs. By beginning at the point of a dissected edge and sweeping in uniplanar motion towards the area of adherence, the flap can...
Flat curved 1 mm spatula blade 30 mm long with marks at 5 mm, 6 mm and 7 mm from tip, polished finish and round knurled handle. Most popular size or model....
Medicine Products: